Immuron Limited (NASDAQ: IMRN)
$2.62
-0.0600 ( -2.24% ) 5.4K
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Market Data
Open
$2.62
Previous close
$2.68
Volume
5.4K
Market cap
$14.88M
Day range
$2.58 - $2.68
52 week range
$1.48 - $5.96
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 5 | Jul 15, 2024 |
6-k | Quarterly Reports | 17 | Jul 09, 2024 |
6-k | Quarterly Reports | 5 | Jul 05, 2024 |
6-k | Quarterly Reports | 7 | Jul 03, 2024 |
6-k | Quarterly Reports | 6 | Jul 02, 2024 |
6-k | Quarterly Reports | 4 | Jun 05, 2024 |
6-k | Quarterly Reports | 20 | May 31, 2024 |
6-k/a | Quarterly Reports | 83 | May 28, 2024 |
6-k | Quarterly Reports | 7 | May 03, 2024 |
6-k | Quarterly Reports | 19 | Apr 23, 2024 |